Aclaris Therapeutics, Inc. ACRS
4.34 USD +0.19 (+4.58%)
At closeNov 12, 2026, 4:33 AM EST
4.39 +0.05 +1.15%
Pre-market · Nov 12, 4:33 AM ET
4.08 Day range 4.40
2.25 52-week range 6.60
- YTD
- +44.19%
- 1 year
- +88.70%
News
defenseworld.net Aclaris Therapeutics (NASDAQ:ACRS) vs. Oncocyte (NASDAQ:IMDX) Financial Contrast Aclaris Therapeutics (NASDAQ: ACRS - Get Free Report) and Oncocyte (NASDAQ: IMDX - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two…
zacks.com Aclaris Therapeutics (ACRS) Reports Q3 Loss, Beats Revenue Estimates Aclaris Therapeutics (ACRS) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to a loss of $0.12 per share a year ago.
benzinga.com Aclaris Therapeutics Q3 EPS $(0.12) Beats $(0.16) Estimate, Sales $1.481M Beat $1.298M Estimate Aclaris Therapeutics (NASDAQ:ACRS) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.16) by 25 percent. This is unchanged from the same period last year.…
globenewswire.com Aclaris Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate and Clinical Update - Initiation of Phase 2b Trial of Modzatinib (ATI-2138) in Lichen Planus Expected in Fourth Quarter of 2026 - - Timeline Reaffirmed for Top Line Results from Phase 2 ADMIRATION Trial of Bosakitug…- benzinga.com Canaccord Genuity Maintains Buy on Aclaris Therapeutics, Raises Price Target to $13 Canaccord Genuity analyst Edward Nash maintains Aclaris Therapeutics (NASDAQ:ACRS) with a Buy and raises the price target from $10 to $13.
benzinga.com Wedbush Maintains Outperform on Aclaris Therapeutics, Lowers Price Target to $8 Wedbush analyst Martin Fan maintains Aclaris Therapeutics (NASDAQ:ACRS) with a Outperform and lowers the price target from $10 to $8.- benzinga.com HC Wainwright & Co. Reiterates Buy on Aclaris Therapeutics, Maintains $16 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Aclaris Therapeutics (NASDAQ:ACRS) with a Buy and maintains $16 price target.
benzinga.com Aclaris Says Early Data Validates Dual-Target Approach for Eczema, Asthma Drug Aclaris Therapeutics announces positive Phase 1b trial data for ATI-052 in eczema and asthma alongside a $50 million public financing round.
benzinga.com Whirlpool Posts Downbeat Q3 Results, Joins HSBC, Hilton Hotels And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session U.S. futures rose, but Whirlpool plunged after a major earnings miss and lowered guidance; HSBC, Armstrong World and others also fell premarket.
benzinga.com Aclaris Therapeutics Prices $50M Offering Of 7,785,714 Shares And Warrants To Purchase 6.5M Shares At $3.50/Unit Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced the pricing of an…
benzinga.com Truist Financial, Regions Financial And Other Big Stocks Moving Lower In Friday’s Pre-Market Session U.S. stock futures mixed; Truist slips after mixed results, while Telkom Indonesia, Loma Negra, Omeros and others fall premarket.
benzinga.com Why Alcoa Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket Alcoa shares rose after Q3 earnings beat estimates; Rubico and others surged, while Nuburu, Jaguar Health and other stocks fell premarket.